). In an attempt to explain these results, the in vivo and in vitro interactions between daptomycin and tobramycin were studied. Tobramycin alone and preincubated with negatively charged phospholipid bilayers (liposomes) was dialyzed against increasing concentrations of daptomycin in buffer at pH 5.4. A significant drop in the concentration of tobramycin was observed when daptomycin was added to the opposite half cells. Furthermore, daptomycin induced a concentration-dependent release of lipid-bound tobramycin. Gold labeling experiments showed that daptomycin could be incorporated into phospholipid layers. Female Sprague-Dawley rats were treated with daptomycin alone, with tobramycin alone, or with the combination over 2 to 10 days. Levels of daptomycin and tobramycin in serum were similar in all groups. The levels of tobramycin in the renal cortex increased significantly with time and, on day 10, reached values of 654 ± 122 and 844 ± 298 ,ug/g of tissue (mean ± standard deviation; not significant) in animals treated with tobramycin and the combination of daptomycin-tobramycin, respectively. No significant difference was observed in the levels of tobramycin in the kidneys between animals treated with tobramycin or the daptomycin-tobramycin combination at any time. By contrast, daptomycin levels were significantly higher in the renal cortexes of animals treated with daptomycin-tobramycin in comparison with those in the renal cortexes of animals treated with daptomycin alone on days 6, 8, and 10 (P < 0.01). For immunogold labeling studies, animals were killed 4 h after a single injection of daptomycin alone or daptomycin in combination with tobramycin. Daptomycin was found throughout the matrixes of the lysosomes of proximal tubular cells of animals treated with daptomycin alone. In animals treated with the combination of daptomycin and tobramycin, daptomycin was associated with intralysosomal myeloid bodies. Our results suggest that daptomycin might attenuate experimental aminoglycoside nephrotoxicity by interacting with the aminoglycoside, perhaps electrostatically, and thereby protecting intracellular targets of toxicity.
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Aminoglycosidic antibiotics are potentially nephrotoxic. Shortly after their injection, these drugs locate sequentially on the brush border membrane of proximal tubular cells (1, 25) , on the membranes of endocytic vacuoles, and into the matrixes of small lysosomes of proximal tubular cells (1) . They accumulate into the lysosomes of these cells (1, 13, 25) , where they induce a lysosomal phospholipidosis characterized by the inhibition of phospholipase activities (19) and a postnecrotic cellular regeneration (20) .
Daptomycin (LY146032) is a cyclic lipopeptide containing an n-decanoyl fatty acid side chain at the amino terminus of the peptide moiety which includes three aspartic acid molecules. This biosynthetic antibiotic is active against gram-positive bacteria and inhibits cell growth by interfering with lipoteichoic acid synthesis. It has been demonstrated that daptomycin protects proximal tubular cells from tobramycin-induced nephrotoxicity without reducing aminoglycoside levels in the renal cortex (5, 29) . Similarly, coadministration of poly-L-aspartic acid with aminoglycosides was also shown to protect against gentamicin and tobramycin nephrotoxicity in vivo (3, 4, 12, 23, 27, 28 (iii) Tobramycin assays. Tobramycin levels were measured by a fluorescence polarized immunoassay (TDX system; Abbott Laboratories, North Chicago, Ill.). Samples were diluted in the TDX buffer to obtain concentrations of between 0 and 8 jig/ml. The sensitivity of the assay (defined as the lowest concentration that could be distinguished from zero with 95% confidence) was 0.18 jig/ml. The coefficient of variation between days was 3.6% at 1 ,ug/ml and 3.4% at 8 ,ug/ml. The presence of daptomycin and/or liposomes had no effect on the assay.
(iv) Preparation of liposomes for gold labeling. Liposomes (5 ml), which were prepared with daptomycin as described above, were first centrifuged for 1 h at 35,000 rpm (model L5-65B; Beckman Instruments, Inc., Mississauga, Ontario, Canada). The supernatant was discarded and the pellet was polymerized with bovine serum albumin (BSA) and 25% glutaraldehyde. Fixation was done in 1% acetate-buffered glutaraldehyde during 1 h at room temperature. Liposomes were postfixed in 1% osmium tetroxide for 1 h, washed in 4 mM acetate buffer (pH 5.4), dehydrated in ascending grades of ethanol, and embedded in Araldite 502 epoxy resin (J.B.EM Services Inc., Pointe-Claire, Quebec, Canada). Ultrathin sections were made with an Ultracut S Ultramicrotome (Leica Canada Inc., Quebec, Quebec, Canada) and were mounted on nickel grids.
(v) Gold labeling. The immunolocalization of daptomycin was done on ultrathin sections by the immunoglobulin G-gold staining two-step method (11, 26) . One side of the grids was first floated for 20 min on a drop of phosphate buffer containing 0.25% BSA. The grids were then placed on a drop of rabbit anti-daptomycin (prepared for us by Berkeley Antibody Company, Richmond, Calif.) diluted 1/1,500. This dilution was found to yield optimal results with high levels of labeling and low background levels. Incubation with daptomycin antisera was carried out for 60 min at room temperature in a moist chamber. The sections were then rinsed with phosphate buffer to remove unbound antibodies and were transferred onto a drop of goat anti-rabbit 30-nm gold (Cederlane Laboratories Ltd., Horby, Ontario, Canada) diluted 1/10 with phosphate buffer-0.02% polyethylene glycol 20,000 for 30 min. At the end of this incubation, sections were washed twice with phosphatebuffered saline (PBS), rinsed in distilled water, and dried.
The phospholipid layers were also localized on ultrathin sections by enzyme-gold labeling as described previously by Coulombe et al. (9) . The other side of the grids was first floated for 10 min on a drop of phosphate buffer containing glycine. They were then placed on a drop of phosphate buffer (pH 8.0) for 5 min. The sections were then transferred onto a drop of phospholipase A2-15-nm gold complex (PLA2; Boehringer Mannheim, Laval, Quebec, Ontario, Canada) diluted 1/4 and were allowed to react for 30 min. At the end of the incubation, the sections were washed twice with phosphate buffer, rinsed in distilled water, and dried. This double labeling was done on opposite side of the grids to eliminate electrostatic attraction between gold particles of different sizes. Staining with uranyl acetate and lead citrate was performed before examination on a Jeol-JEM 1010 electron microscope (Soquelec, Montreal, Quebec, Canada) at 60 kV.
(vi) Gold labeling controls. Concurrent control experiments for assessing the specificity of immunolabeling were performed as follows: (i) absorption of antibody with its specific antigen before performing the labeling protocol to verify the specificity of the antigen-antibody interaction, (ii) incubation with goat anti-rabbit 30-nm gold alone to identify its nonspecific absorption to the tissue section, (iii) absorption of PLA2-gold with the three components of liposomes (cholesterol, phosphatidylcholine, phosphatidylinositol) to verify the specificity of the enzyme-substrate reaction, and (iv) addition of an excess of free PLA2 (0.5 mg/ml) to the incubation mixture.
In vivo experiments. pLg/ml) were prepared in blank cortex homogenized in sodium polyanetholesulfonate (2%). Standard curves were also prepared in the presence of different concentrations of tobramycin and showed the efficacy of polyanetholesulfonate in inhibiting the antimicrobial activity of tobramycin. The homogenates were sonicated with a sonicator (model 375; Bionetics Ltd., Montreal, Quebec, Canada). The lower limit of sensitivity of the microbiological assay was 0.4 pLg/ml of serum and 10 ,ug/g of tissue. The recovery of daptomycin in renal homogenate was 91.3% ± 12.2%. The interday coefficients of variation were 2.3% at 20 ,ug/ml and 8.6% at 5 pug/ml. The standard curve was linear from 0.4 to 100 1ig/ml, with a coefficient of correlation of 0.993. (iii) Tobramycin assay. The accumulation of tobramycin in renal cortical tissue was measured by a fluorescence polarized immunoassay. Briefly, samples of kidney were homogenized in distilled water with a Tissue-Tearor apparatus. The homogenates were also sonicated and diluted in the TDX buffer (Abbott Laboratories) to obtain concentrations of between 0 and 10 ,ug/ml. Standards were prepared in blank homogenates of renal cortical tissue at the same dilution used for the tissue assays. The lower limit of sensitivity of the assay was 3 p,g/g of tissue. The presence of daptomycin had no effect on the assay. The recovery of tobramycin in renal homogenate were 99.1% ± 6.9%. The interday coefficients of variation were 3.6% at 1 ,ug/ml and 3.4% at 8 ,ug/ml.
(iv) Subcellular distribution: animals and treatment. Another group of female Sprague-Dawley rats weighing between 175 and 200 g was used to determine the subcellular distribution. The rats had free access to food and water throughout the experiment. Animals were anesthetized with pentobarbital sodium (45 mg/kg of body weight), and a polyethylene catheter (PE-50; Intramedic, Clay Adams, Parsippany, N.J.) prefilled with 0.9% NaCl was inserted into the right jugular vein. The other end of the catheter was guided subcutaneously until it emerged through a hole made in the skin of the neck and secured. After recovering from anesthesia, rats were returned to their cages and were left undisturbed overnight. On the following day, animals were given, through the catheter, a single intravenous injection of daptomycin (100 mg/kg) alone or in combination with tobramycin (40 mg/kg). Four animals of each group were killed 4 h after the injection. At the time of sacrifice, one saline-injected rat was also killed as a control. All animals were killed by decapitation and were bled. A midline abdominal incision was made, the right kidney of each animal was removed and bisected, and the renal cortex was dissected.
A small piece of cortex was cut into small blocks of 1 mm3, and the blocks were placed into drops of 0.5% phosphatebuffered glutaraldehyde and were left overnight in the same fixative at 4°C. The blocks were then washed in 0.1 M phosphate buffer (pH 7.4), dehydrated in ascending grades of ethanol (50 to 99%), and embedded in Araldite 502 epoxy resin (J. B. EM Services Inc.). Ultrathin sections (silver to light gold) were cut with an ultramicrotome (Ultracut S), mounted onto nickel grids, and processed for immunocytochemistry.
(v) Immunogold labeling. To determine the subcellular localization of daptomycin, the antibody-gold complex technique was used (26) . Each grid was first floated on a drop of PBS containing 0.25% BSA (Sigma Chemical Co.) for 20 min. Each grid was then placed on a drop of rabbit anti-daptomycin antiserum (diluted 1/1,500). Incubations with antisera were carried out for 60 min at room temperature in a moist chamber. The sections were then rinsed with PBS to remove unbound antibody and incubated for 30 min on a drop of goat anti-rabbit-gold (30-nm diameter) diluted 1/10. At the end of the incubation, the sections were washed twice with PBS, rinsed with distilled water, and dried. Staining of the grids with uranyl acetate and lead citrate was performed before they were examined on the electron microscope at 60 kV.
(vi) Immunogold controls. Several concurrent control experiments for assessing the specificity of the immunolabeling were performed, as follows: (i) incubation with goat anti-rabbit-gold alone to identify the nonspecific absorption into the sections, (ii) absorption of antibody with its specific antigen before the labeling protocol to verify the specificity of the antigenantibody interaction, (iii) replacement of the specific antibody by normal serum, and (iv) immunogold labeling of the renal cortical tissues of saline-treated rats.
Statistical analysis. Determination (Fig. 1 ). Significant differences were observed between the concentrations of tobramycin measured in the absence of daptomycin and those obtained with daptomycin at concentrations of 1, 5, and 10 mg/ml. A transfer of tobramycin, but of a smaller magnitude, was observed when tobramycin preincubated with liposomes was loaded initially. A significant difference was observed between tobramycin and tobramycin plus liposomes at daptomycin concentrations of 5 mg/ml (P < 0.01) and 10 mg/ml (P < 0.05). These effects were also pH dependent. In fact, daptomycin bound less tobramycin at pH 7.4 than at pH 5.4 (data not shown). Experiments similar to those described above were repeated, except that daptomycin was replaced by poly-L-lysine, a polycationic molecule, to verify that the displacement of tobramycin from one side to the other side of the dialysis cells was not only a result of a charge density. In fact, the concentrations of tobramycin measured in the original half cells increased as the concentrations of poly-L-lysine increased in the opposite cells, which was expected (data not shown).
(ii) Influence of ionic strength on tobramycin binding to daptomycin. The effects of ionic strength on the binding of tobramycin to daptomycin are presented in Fig. 2 . Results are given as the quantity of aminoglycosides bound to daptomycin at a concentration of 5 mg/ml. The levels of tobramycin bound to daptomycin decreased as the ionic strength increased.
(iii) Equilibrium dialysis of tobramycin against liposomes, daptomycin, and liposomal daptomycin. Figure 3 beginning of the equilibrium dialysis. Results are presented as the percentage of the concentration of aminoglycosides loaded initially in the opposite half cells. Figure 3 shows that daptomycin and liposomal daptomycin bind significantly more tobramycin than do liposomes alone (P < 0.05). Significantly more tobramycin was measured in the presence of liposomal daptomycin than was measured with daptomycin alone (P <0.05).
(iv) Localization of daptomycin and phospholipids by gold labeling. Figure 4 shows the immunohistochemical localization of daptomycin and phospholipids on ultrathin sections. Phospholipid layers were easily seen on ultrathin sections by electron microscopy, and 15-nm gold particles were associated with these artificial membranes. Daptomycin (30-nm gold particles) was seen essentially over phospholipid layers, suggesting a direct binding of daptomycin to the membrane. The control experiments proved the high specificity of the gold labeling. The absorption of the antibody with different antigens resulted in the abolition of the labeling.
In vivo experiments. (i) Levels of daptomycin and tobramycin in serum and cortical tissue in vivo. The levels of daptomycin and tobramycin in serum were similar in animals treated with the drug alone and in animals given the combination after 2, 4, 6, 8, and 10 days of treatment. Figure 5 shows the concentrations of daptomycin and tobramycin in the renal cortexes. The levels of tobramycin in the renal cortexes increased significantly with time and on day 10 reached values of 654 ± 122 and 844 ± 298 ,ug/g of tissue (mean ± standard deviation. The difference was not significant in animals treated with tobramycin and daptomycin-tobramycin, respectively. No significant difference in the levels of tobramycin in renal cortical tissue was observed between animals treated with tobramycin or daptomycin-tobramycin at any time. By contrast, daptomycin levels were significantly higher in the renal cortexes of animals treated with daptomycin-tobramycin than in those of animals treated with daptomycin alone on days 6 (ii) Subcellular distribution of daptomycin. Figure 6 shows the subcellular distribution of daptomycin in animals given a single injection of daptomycin (100 mg/kg) alone or in combination with tobramycin (40 mg/kg). At 4 h after the injection, daptomycin was essentially seen over the lysosomes of proximal tubular cells (Fig. 6A) . Gold particles were distributed uniformly throughout the matrixes of the lysosomes. In animals treated with the combination daptomycin-tobramycin, gold particles were located over small myeloid bodies inside the lysosomes (Fig. 6B) . Recent data from our laboratory show the localization of daptomycin over the myeloid bodies in animals treated during 10 days with the combination daptomycin-tobramycin (2).
DISCUSSION
Several strategies for reducing aminoglycoside nephrotoxicity in experimental animals have been investigated. Calcium, an effective competitor of aminoglycoside binding to membranes, has been used orally to increase the amount of calcium delivered to proximal tubular cells. Humes et al. (14) and Bennett et al. (7) showed that calcium loading significantly reduces gentamicin nephrotoxicity without modifying peak levels in the renal cortex. Because large amounts of calcium are required to achieve this protective effect, it has no practical use. Nitrodepine, a calcium channel inhibitor, was also found to be effective in protecting rats from gentamicin toxicity (21).
Kacew (16) also demonstrated that the simultaneous administration of pyridoxal 5'-phosphate and gentamicin during 2 weeks could prevent aminoglycoside-induced phospholipidosis in male rats. All factors that have been recognized to modulate aminoglycoside nephrotoxicity are associated with disturbed levels of these drugs in the kidneys, and their clinical application remains uncertain.
The polycationic nature of aminoglycosides and the presence of anionic binding sites on the membrane have been shown to be capital factors in the interaction of these drugs with isolated brush border membrane vesicles (15, 24) . An increase in the content of acidic phospholipids and a decrease in the pH and ionic strength enhanced the binding of gentamicin to anionic phospholipids, suggesting that the interaction of aminoglycosides with anionic phospholipids is mainly electrostatic (19) . Stepwise computer conformational analysis of aminoglycoside-phospholipid systems has suggested that hydrophobic interactions and bilayer penetration are potentially important modifiers of this simple electrostatic binding (8) .
Lysosomal phospholipases Al and A2, which are specifically inhibited by aminoglycosides, apparently require negative charges on the substrate to achieve their full activity. In fact, no appreciable activity of these enzymes was observed in membranes devoided of anionic phospholipids (22) . Moreover, the enzymatic activation provided by anionic phospholipids was shown to correlate directly with their concentration (22) . It The lipopeptidic antibiotic daptomycin was shown to inhibit both tobramycin-induced lysosomal phospholipidosis and increased cellular regeneration (5) as well as the development of functional renal failure (29) in the presence of similar or even higher aminoglycoside levels in the renal parenchyma. By contrast, Kreft et al. (18) observed a dose-dependent and a reversible increase in urinary tubular cell elimination following daptomycin therapy (10 to 250 mg/kg) in rats; these effects were enhanced by using a combination of daptomycin and tobramycin.
The present in vitro study was thus an attempt to unravel the mechanism of protection afforded by daptomycin against aminoglycoside nephrotoxicity. Results of the first set of experiments indicate that daptomycin binds tobramycin and causes a release of the liposome-bound aminoglycosides. These effects were dependent on the concentration of daptomycin. The experiments were performed at pH 5.4, which has been reported to be the intralysosomal pH (10) . These changes were dependent on the ionic strength, suggesting that these interactions are electrostatic in nature. Our data obtained with poly-L-lysine are consistent with a direct interaction between daptomycin and tobramycin.
Previous in vivo experiments showed that daptomycin protects renal tubular cells against aminoglycoside nephrotoxicity without decreasing the levels of these drugs in renal cortical tissue. Since no concomitant histopathological alteration toward subcellular structure in proximal tubular cells or other cortical cells was observed (5) , it can be inferred that the protection is due to neutralization of the toxicity of these drugs rather than to their tissue or cellular redistribution. One cannot exclude a complexation between daptomycin and tobramycin in serum, in urine, or inside the lysosomes that would prevent an inhibitory effect of these drugs toward phospholipid catabolism.
Kreft et al. (18) reported an intrarenal accumulation of daptomycin when daptomycin was given during 5 days at doses of 100 mg/kg, but these levels declined rapidly 48 h after the fifth dose. Our present data show that the accumulation of daptomycin in renal tissue is clearly dependent on the levels of tobramycin in tissue. Are these changes due to a complexation between daptomycin and tobramycin or between daptomycin and the accumulated phospholipids seen inside the lysosomes? Looking at the chemical structure of the lipopeptide, one can infer that the most likely type of interaction is the insertion of a daptomycin hydrophobic moiety into the bilayer core. Infrared spectroscopic measurements confirmed this, since daptomycin was found to induce a decrease in the gel-to-fluid lipidic transitions of dimyristoylphosphatidylglycerol and dipalmitoylphosphatidylcholine (6) . Under the experimental conditions used in the present study, daptomycin alone and liposomes prepared with daptomycin bound significantly more tobramycin than did liposomes alone. Immunogold labeling of liposomes prepared with daptomycin in vitro as well as our immunogold localization of daptomycin in vivo shown in the present study and in a recent paper (2) suggest that this drug can insert within phospholipid layers. Daptomycin incorporated into phospholipidic layers in the lysosomes of proximal tubular cells by its hydrophobic moiety can bind aminoglycosides by its free peptidic region at the surface of the phospholipidic membrane, especially through the negative charges afforded by L-aspartic acid.
Poly-L-aspartic acid was also shown to protect against the renal toxicity of aminoglycosides without reducing the levels of these drugs in renal cortical tissue. Williams and Hottendorf (27) were the first to report the in vivo protective effect of poly-L-aspartic acid against gentamicin nephrotoxicity in experiments in animals. More recently, Gilbert et al. (12) demonstrated the ability of poly-L-aspartic acid to prevent the development of functional renal failure in animals treated with gentamicin, despite a 10-fold increase in the accumulation of aminoglycosides in renal tissue. Beauchamp et al. (3, 4) showed that poly-L-aspartic acid completely suppresses the development of early renal alterations induced by gentamicin (lysosomal phospholipidosis and increased cellular proliferation). In vitro experiments done by Kishore et al. (17) demonstrated that poly-L-aspartic acid optimally binds gentamicin at an acidic pH, displaces it from negatively charged liposomes, and restores the activity of gentamicin-inhibited lysosomal phospholipase A1.
The results of the present study are consistent with an electrostatic interaction between daptomycin and tobramycin. Although this electrostatic interaction was observed at a high daptomycin:tobramycin ratio, a condition that probably does not prevail in vivo, our overall results suggest that daptomycin prevents the development of lysosomal phospholipidosis by acting on the complex between aminoglycosides and membrane phospholipids inside the lysosomes of proximal tubular 
